Table 1. Baseline demographics and clinical characteristics for all randomised and treated patients with C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) measurements available.

	ATTAIN		AIM
	Abatacept + DMARDs n = 171	Placebo + DMARDs n = 75	Abatacept + MTX n = 351	Placebo + MTX n = 155
Age, years	52.5 (12.1)	52.5 (12.0)	50.8 (12.7)	49.5 (11.6)
Gender, % female	77.2	80.0	77.2	83.2
Race, % Caucasian	96.5	93.3	87.7	86.5
Disease duration, years	12.0 (8.1)	11.7 (9.0)	8.5 (7.1)	8.9 (7.0)
Tender joints	30.9 (13.4)	31.0 (13.6)	31.1 (12.8)	33.7 (13.9)
Swollen joints	22.6 (10.4)	22.1 (10.1)	21.3 (8.3)	22.3 (8.3)
Erosion score*	N/A	N/A	22.4 (18.3)	22.1 (19.7)
Joint space narrowing score*	N/A	N/A	23.3 (20.1)	23.7 (21.3)
Total score*	N/A	N/A	45.7 (37.4)	45.8 (39.8)
Pain assessment, 100 mm VAS	69.5 (20.5)	68.0 (19.0)	63.1 (21.1)	67.3 (18.9)
Physical function, HAQ-DI	1.8 (0.5)	1.7 (0.6)	1.7 (0.7)	1.7 (0.6)
Patient global assessment, 100 mm VAS	68.2 (19.6)	66.7 (22.0)	63.2 (20.9)	63.8 (20.6)
Physician global assessment, 100 mm VAS	67.7 (17.7)	63.7 (18.2)	69.3 (15.3)	68.2 (15.9)
Levels of CRP, mg/dl	4.4 (3.6)	3.5 (3.3)	3.3 (3.2)	2.5 (2.1)
ESR, mm/h	49.9 (27.7)	43.7 (26.9)	44.1 (23.5)	43.0 (24.5)
DAS28 (CRP)	6.5 (0.9)	6.4 (0.8)	6.4 (0.8)	6.4 (0.8)
DAS28 (ESR)	6.9 (1.0)	6.8 (1.0)	6.8 (0.9)	6.9 (0.8)

Data are mean (SD) unless otherwise stated.

*Values represent baseline readings for all patients with radiographic data at day 365 (n = 328 for abatacept; n = 137 for placebo).

AIM, Abatacept in Inadequate responders to Methotrexate; ATTAIN, Abatacept Trial in Treatment of Anti-TNF INadequate responders; DAS28, 28-joint Disease Activity Score; DMARD, disease-modifying antirheumatic drug; HAQ-DI, Health Assessment Questionnaire Disability Index; MTX, methotrexate; N/A, not applicable; VAS, visual analogue scale.